Nursing · Independent exam preparation
Women's Health Care Nurse Practitioner Study Guide
Develop clinical reasoning with 60 selected WHNP-BC concepts, 20 practice questions and 20 flashcards covering all six examination domains.
By CertMedbry · Updated 28 October 2026
Practise complaint-directed assessment, interpretation of findings, treatment selection and recognition of reproductive and pregnancy emergencies. This selective guide develops 60 concepts across all six domains of NCC's Women's Health Care Nurse Practitioner examination. Use the official 2026 examination outline on pages 7–9 as the full examination preparation framework, supplemented by its detailed study topics. These concepts do not cover every listed disorder, procedure or competency.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification and educational pathway does this guide address?
This guide addresses National Certification Corporation Women's Health Care Nurse Practitioner board certification, awarding WHNP-BC. Eligible preparation can include qualifying master's, DNP and post-master's WHNP programs. NCC's educational and licensure requirements apply, including its specific conditions for Canadian applicants. Certification does not itself grant jurisdictional authority to practise.
NCC — Women's Health Care Nurse Practitioner · 2026 Candidate Guide: Women's Health Care Nurse Practitioner
How many questions are on the examination, and how long is it?
NCC specifies 175 multiple-choice questions in three hours. Of these, 150 are scored and 25 are embedded pretest questions that do not contribute to the final result. Prepare to answer the entire examination because pretest questions are embedded.
2026 Candidate Guide: Women's Health Care Nurse Practitioner
What question format does the actual examination use?
The 2026 guide describes a stem with three possible answers: one correct answer and two distractors. Questions assess knowledge and application. Laboratory results appear in conventional units with international units in parentheses. The independent practice questions in this guide use four options to support comparison of clinical alternatives.
2026 Candidate Guide: Women's Health Care Nurse Practitioner
How is the examination delivered?
NCC offers computer testing at a test center and live remote proctoring. The guide describes questions presented in different random orders. It does not identify the examination as computer adaptive. Item response theory and Rasch analysis describe psychometric analysis and scoring; their use does not establish adaptive delivery.
NCC — Women's Health Care Nurse Practitioner · 2026 Candidate Guide: Women's Health Care Nurse Practitioner
Which outline and domain weights apply?
The guide labeled 2026 gives examination content on pages 7–9 without stating a separate outline effective date. Its domain weights are Assessment, Diagnostic Testing and Interpretation 12%; Primary Care 13%; Gynecologic and Reproductive Health 33%; Obstetrics 29%; Pharmacology 10%; and Professional Practice Issues 3%. Use these outline percentages rather than the different groupings in the illustrative score report.
2026 Candidate Guide: Women's Health Care Nurse Practitioner
How are passing performance and results reported?
NCC uses criterion-referenced scoring and equating across examination forms. There is no fixed percentage passing level and no penalty for incorrect answers. Reports provide pass/fail status and descriptive content-area feedback. Results are not provided immediately after testing; official results become available through the candidate's NCC account.
2026 Candidate Guide: Women's Health Care Nurse Practitioner · NCC — Women's Health Care Nurse Practitioner
How should this selective guide fit into preparation?
The 60 concepts comprise 7 assessment, 8 primary care, 20 gynecologic and reproductive health, 17 obstetrics, 6 pharmacology and 2 professional practice concepts. The questions and flashcards each use domain allocations of 2, 3, 6, 6, 2 and 1. These approximate the outline weights but do not establish comprehensive coverage. Use the official outline to identify all additional preparation needs.
2026 Candidate Guide: Women's Health Care Nurse Practitioner
An independent educational resource for NCC's entry-level advanced practice WHNP-BC certification. The practice questions and flashcards are original learning materials, not official NCC examination items or an NCC-endorsed product.
Outline used: NCC 2026 Candidate Guide: Women's Health Care Nurse Practitioner (WHNP-BC), examination outline on pages 7–9; verified on 2026-10-11. The guide states the year 2026 but no separate outline effective date. The workbook label matches NCC's current examination name; the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Assessment, Diagnostic Testing and Interpretation12%
1.Which laboratory findings establish iron deficiency with anemia?
A complete blood count establishes whether hemoglobin is reduced, while iron studies help determine whether insufficient iron explains the anemia. Ferritin reflects stored iron; a low result supports depleted stores. Identifying anemia and identifying its cause are separate diagnostic tasks. Fatigue, pallor and dizziness support concern but cannot establish iron deficiency without appropriate evaluation.
Apply it
A patient with prolonged menstrual bleeding has reduced hemoglobin and low ferritin. Recognize iron-deficiency anemia, assess the bleeding history and determine replacement needs while investigating why iron was lost.
Common pitfall: Low hemoglobin alone does not prove iron deficiency. Treating tiredness empirically without investigating the laboratory pattern can overlook another cause of anemia.
2.How should history and examination distinguish causes of pelvic pain?
Establish onset, location, severity, menstrual relationship, pregnancy possibility, bleeding, discharge, sexual exposures and urinary or bowel symptoms. Assess vital signs and abdominal tenderness before the pelvic examination. Speculum examination identifies discharge, cervical lesions and the apparent bleeding source. Bimanual examination localizes cervical motion, uterine or adnexal tenderness. In an at-risk patient with compatible pain and no better cause, any one of these tenderness findings supports presumptive PID treatment. Severe worsening pain or fainting changes urgency. See [NHS pelvic pain guidance](https://www.nhs.uk/symptoms/pelvic-pain/).
Apply it
Discharge with cervical motion tenderness supports PID assessment; severe pain with near-syncope and possible pregnancy requires emergency evaluation for internal bleeding rather than completion of a routine office examination.
Common pitfall: Tenderness is not specific to PID. Do not allow an STI history to obscure ectopic pregnancy or another surgical emergency, and do not require all three pelvic tenderness findings.
3.Which specimen best supports urogenital chlamydia screening?
Nucleic acid amplification testing is recommended for detecting urogenital Chlamydia trachomatis. A vaginal swab is an optimal specimen for patients with vaginal anatomy. In clinical settings, appropriately collected patient swabs perform comparably to clinician-collected swabs. First-catch urine is an optimal specimen for male urethral screening. Rectal exposure can require site-specific testing; a negative urogenital result does not exclude rectal infection.
Apply it
An asymptomatic patient prefers to avoid a speculum examination. Offer a patient-collected vaginal swab using approved instructions. Ask about specific exposure sites to determine whether additional specimens are indicated.
Common pitfall: Cervical cytology and routine bacterial urine culture do not substitute for chlamydia NAAT. Gender identity and partner labels do not establish which sites were exposed.
4.Which findings change the urgency of male reproductive assessment?
For scrotal pain, ask about sudden versus gradual onset, urinary symptoms, urethral discharge, sexual practices and instrumentation. Inspect for swelling and palpate each testis, epididymis and spermatic cord to localize tenderness. Unilateral epididymal swelling and tenderness can support epididymitis. Sudden severe unilateral pain, especially without evidence of urinary or urethral inflammation, raises concern for testicular torsion and requires immediate urologic evaluation because blood supply is threatened. See [CDC epididymitis guidance](https://www.cdc.gov/std/treatment-guidelines/epididymitis.htm).
Apply it
A patient with abrupt severe scrotal pain needs immediate torsion assessment. A gradual inflammatory presentation still requires testing and assessment for torsion when the diagnosis is uncertain.
Common pitfall: Sexual activity does not prove infectious epididymitis. Partial torsion can resemble epididymitis on ultrasound, so unresolved clinical concern must not be dismissed by a superficially reassuring scan.
2026 Candidate Guide: Women's Health Care Nurse Practitioner
5.How should a breast complaint direct history and physical examination?
Clarify whether the concern is focal pain, a persistent lump, nipple discharge or skin change, and establish its duration and relationship to the menstrual cycle. Inspect the breasts and nipples, palpate the reported area and characterize any mass and tenderness. Determine whether discharge is spontaneous or only expressed. A mass, unexplained skin change or spontaneous discharge changes the task from routine screening to diagnostic evaluation. ASRM's targeted examination guidance identifies breast tenderness, masses, skin changes and discharge as findings requiring directed assessment.
Apply it
A persistent palpable lump requires diagnostic imaging despite a recent normal screening mammogram. ASRM identifies ultrasound as the preferred initial modality below age 30 and diagnostic mammography at age 30 or older.
Common pitfall: A screening interval does not govern evaluation of a new symptom. Do not dismiss a patient-identified persistent finding simply because it is painless or screening was recently normal.
Fertility evaluation of infertile women: a committee opinion (2026) | American Society for Reproductive Medicine | ASRM · USPSTF — Breast Cancer: Screening
6.Why does condition prevalence change positive predictive value?
Positive predictive value is the number of true-positive results divided by all positive results. It estimates how often a positive result represents the condition. When prevalence is low, false positives can constitute a substantial share of positive results despite strong sensitivity and specificity. Sensitivity instead asks what proportion of affected individuals screen positive.
Apply it
If 18 affected pregnancies and 98 unaffected pregnancies screen positive, positive predictive value is 18 divided by 116, approximately 15.5%. The denominator includes every positive result.
Common pitfall: Do not substitute sensitivity for the probability of disease after a positive result. The false-positive rate also uses a different denominator: all unaffected individuals.
7.How is pregnancy location evaluated when ectopic pregnancy is possible?
A positive pregnancy test detects pregnancy-associated hormone but does not identify implantation location. Transvaginal ultrasound evaluates the uterus and adnexa. An extrauterine gestational sac containing a yolk sac or fetal pole, separate from the ovary, supports a tubal ectopic diagnosis. An empty uterus alone does not establish ectopic pregnancy. Interpret symptoms, ultrasound and serial hCG together; hCG trends assess trophoblastic activity rather than independently locating implantation.
Apply it
A stable patient with pain, a positive pregnancy test and no located pregnancy needs structured diagnostic follow-up. Free intraperitoneal fluid with worsening pain or instability raises concern for hemorrhage and changes urgency.
Common pitfall: A single hCG value cannot prove pregnancy location. A previous follow-up plan must not delay emergency care when symptoms worsen.
Primary Care13%
8.When does USPSTF recommend routine breast screening?
The 2024 USPSTF recommendation supports biennial mammography from ages 40 through 74 for its covered population. Specified high-risk circumstances, including pathogenic BRCA variants, previous breast cancer and high-dose chest radiation at a young age, require a different framework. A new breast symptom requires diagnostic evaluation rather than waiting for a routine screening interval.
Apply it
Recommend biennial mammography to an eligible asymptomatic 42-year-old. Evaluate a newly reported mass diagnostically even if a recent screening mammogram was normal.
Common pitfall: For dense breasts with an otherwise negative mammogram, insufficient evidence for supplemental ultrasound or MRI does not mean universal benefit or universal lack of benefit. Interpret the recommendation within its population.
9.How should persistent nonpregnant hypertension be distinguished from an emergency?
Repeat an elevated measurement and use a series of home or ambulatory readings when appropriate to establish persistence. Confirmed hypertension requires cardiovascular risk assessment, lifestyle treatment and medication according to severity and comorbidity. Common drug classes include thiazide diuretics, ACE inhibitors or ARBs, and calcium channel blockers. Severe pressure above 180 systolic or 120 diastolic with chest pain, dyspnea or neurologic symptoms requires emergency care. See [AHA blood-pressure guidance](https://www.heart.org/en/health-topics/high-blood-pressure/understanding-blood-pressure-readings) and [NHLBI treatment guidance](https://www.nhlbi.nih.gov/health/high-blood-pressure/treatment).
Apply it
For repeated uncomplicated elevation, establish sustained pressure and initiate longitudinal management. Severe elevation with weakness or difficulty speaking requires emergency assessment rather than a routine medication adjustment.
Common pitfall: One measurement does not define chronic control. Pregnancy uses different emergency thresholds, and pregnancy plans affect medication selection.
2026 Candidate Guide: Women's Health Care Nurse Practitioner
10.How does osteoporosis screening differ before and after age 65?
USPSTF recommends osteoporosis screening for women aged 65 or older. For postmenopausal women younger than 65, identify additional risk factors and use a clinical risk assessment tool to determine whether screening is warranted. Low body weight, parental hip fracture, smoking and excessive alcohol use are relevant risks. Central DXA measures bone mineral density.
Apply it
Recommend screening to an eligible 67-year-old. For a 58-year-old with low weight and parental hip fracture, assess fracture risk before deciding on DXA.
Common pitfall: Menopause alone does not automatically establish the younger-patient indication. Known osteoporosis, fragility fracture or secondary bone loss requires clinical evaluation beyond this routine screening pathway.
11.How should diabetes screening lead to classification and prevention?
USPSTF recommends screening asymptomatic nonpregnant adults aged 35–70 with overweight or obesity; additional risks can justify earlier testing. Prediabetes includes fasting glucose 100–125 mg/dL, A1c 5.7%–6.4%, or two-hour glucose 140–199 mg/dL after a 75-g load. Diabetes-range results include fasting glucose at least 126 mg/dL, A1c at least 6.5%, or two-hour glucose at least 200 mg/dL. Confirm an asymptomatic patient's diabetes diagnosis with repeat testing. Offer or refer patients with prediabetes to an effective preventive intervention.
Apply it
An A1c of 6.7% calls for confirmation. A prediabetes result calls for an accessible structured dietary and physical activity intervention rather than waiting for symptoms.
Common pitfall: These nonpregnant thresholds do not replace pregnancy-specific criteria. Symptoms require diagnostic evaluation even outside preventive screening age or BMI criteria.
12.How do thyroid findings guide initial treatment and referral?
Fatigue, cold intolerance, dry skin and menstrual changes suggest hypothyroidism but require biochemical confirmation. High TSH with low free T4 supports primary hypothyroidism; low TSH with elevated free T4 suggests hyperthyroidism. Confirmed hypothyroidism is treated with levothyroxine, with testing approximately six to eight weeks after initiation or dose adjustment. Severe altered consciousness can indicate decompensated disease requiring emergency care. See [NIDDK thyroid testing](https://www.niddk.nih.gov/health-information/diagnostic-tests/thyroid) and [hypothyroidism treatment](https://www.niddk.nih.gov/health-information/endocrine-diseases/hypothyroidism).
Apply it
Examine thyroid size, texture and nodularity. A rapidly growing, asymmetric or nodular thyroid warrants ultrasound and possible specialist assessment; pregnancy requires prompt review of replacement needs.
Common pitfall: Symptoms alone do not establish thyroid disease. Pregnancy and estrogen exposure can alter binding proteins and total T4, making interpretation of the actual assay important.
13.How should an asthma flare change immediate and continuing care?
Airway inflammation and tightening produce worsening cough, wheeze, chest tightness and breathlessness. Use the prescribed reliever promptly and follow the asthma action plan. Persistent severe breathing difficulty or failure to improve after reliever treatment requires emergency care. A recent severe attack, hospitalization or substantial reliever use increases concern. After stabilization, review controller use, adherence and the action plan. See [NHLBI asthma attack guidance](https://www.nhlbi.nih.gov/health/asthma/attacks).
Apply it
A patient whose breathlessness persists despite the prescribed rescue treatment needs urgent escalation. Repeated attacks also require reassessment of preventive treatment rather than repeated rescue refills alone.
Common pitfall: Temporary symptom relief does not establish adequate long-term control. Do not delay emergency assessment while completing routine office testing when breathing remains very difficult.
2026 Candidate Guide: Women's Health Care Nurse Practitioner
14.Why must iron replacement be paired with cause and severity assessment?
Iron deficiency develops when available absorbed iron cannot meet losses or needs. Heavy menstrual bleeding, gastrointestinal bleeding, childbirth-related blood loss and impaired absorption are important contributors. Oral iron replaces iron but does not stop ongoing bleeding or correct every absorption problem. Serious anemia can cause dyspnea or chest pain, requiring assessment of current stability as well as laboratory findings.
Apply it
Repeated recurrence after replacement warrants assessment of continuing losses, absorption and medication exposure. New chest discomfort or substantial breathlessness changes urgency and cannot be managed by a routine refill alone.
Common pitfall: Do not attribute every case to diet or menstruation. Improvement during supplementation establishes a response, but recurrence can reveal that the underlying cause remains active.
15.How does symptomatic urinary disease differ from asymptomatic bacteriuria?
Dysuria, urgency, frequency and lower abdominal discomfort suggest cystitis. Fever, chills, flank or back pain, nausea or vomiting raise concern for kidney infection. Evaluate symptoms and urine findings, and select antibiotics according to likely organisms, allergies and clinical circumstances; severe illness may require intravenous treatment. See [NIDDK urinary symptoms](https://www.niddk.nih.gov/health-information/urologic-diseases/bladder-infection-uti-in-adults/symptoms-causes) and [treatment guidance](https://www.niddk.nih.gov/health-information/urologic-diseases/bladder-infection-uti-in-adults/treatment). USPSTF recommends against routine asymptomatic bacteriuria screening in its covered nonpregnant adult population.
Apply it
A patient with dysuria and suprapubic discomfort needs diagnostic evaluation. Fever with vomiting and flank pain warrants prompt assessment for pyelonephritis and suitability for outpatient treatment.
Common pitfall: The recommendation against asymptomatic screening does not apply to symptomatic illness. Bacterial growth alone does not establish that antibiotics explain or treat every urinary complaint.
Gynecologic and Reproductive Health33%
16.Which findings satisfy clinical criteria for bacterial vaginosis?
Bacterial vaginosis is vaginal dysbiosis involving reduced Lactobacillus predominance and increased mixed anaerobic organisms. Amsel diagnosis requires at least three of four findings: homogeneous thin discharge, clue cells, vaginal pH above 4.5 and fishy odor before or after potassium hydroxide. Clue cells are vaginal epithelial cells coated with adherent bacteria. On Gram stain, Nugent scores of 7–10 support BV; 4–6 indicate intermediate microbiota.
Apply it
Thin discharge, pH 5.2 and clue cells provide three findings supporting a clinical BV diagnosis, even without a documented positive odor test.
Common pitfall: All four findings are not required. One nonspecific feature, Gardnerella culture, cervical cytology or an intermediate Nugent score does not independently establish BV.
17.When should PID be treated, and what outpatient regimen is recommended?
Presumptively treat an at-risk patient with pelvic pain, no better identified cause and cervical motion, uterine or adnexal tenderness; one tenderness finding suffices. For an appropriate nonpregnant outpatient, CDC recommends ceftriaxone 500 mg IM once plus doxycycline 100 mg and metronidazole 500 mg orally twice daily for 14 days. The combination addresses gonorrhea, chlamydia and anaerobic organisms.
Apply it
Begin treatment without awaiting cervical NAAT results and arrange reassessment within 72 hours. Assess pregnancy, medication hypersensitivity, illness severity and oral tolerance before selecting outpatient care.
Common pitfall: Negative cervical testing does not exclude upper-tract infection. Ceftriaxone dosing increases to 1 g for patients over 150 kg with documented gonococcal infection.
18.Which PID findings require admission or reassessment?
Admission indications include pregnancy, tubo-ovarian abscess, an unexcluded surgical emergency, severe illness or vomiting, inability to tolerate or follow oral treatment, and failure to respond to outpatient therapy. Improvement should occur within three days. Lack of improvement by 72 hours warrants hospitalization, regimen review and additional diagnostic assessment. Age alone does not determine the setting of care.
Apply it
Persistent tenderness after 72 hours or an identified abscess requires escalation. An IUD generally may remain when treatment begins, with removal considered if improvement is absent within 48–72 hours.
Common pitfall: Normal blood pressure does not neutralize an abscess or inability to take medication. Immediate IUD removal is not required for every PID diagnosis.
CDC — Pelvic Inflammatory Disease · CDC — Intrauterine Contraception
19.How is symptomatic bacterial vaginosis treated?
CDC recommends treating symptomatic bacterial vaginosis. Recommended options include metronidazole 500 mg orally twice daily for seven days; metronidazole gel 0.75%, one full 5-g applicator intravaginally once daily for five days; or clindamycin cream 2%, one full 5-g applicator intravaginally at bedtime for seven days. Choose according to clinical circumstances, allergies and formulation preferences. Routine follow-up is unnecessary if symptoms resolve, but recurrence warrants reassessment.
Apply it
Discuss appropriate oral or vaginal options and provide the administered quantity, route, frequency and duration for the selected formulation.
Common pitfall: Concentration alone does not specify a dose. Clindamycin cream is oil based and can weaken latex condoms and diaphragms for five days after use.
20.How does chlamydia follow-up address reinfection?
Many infections detected after treatment represent reinfection from untreated or new partners rather than antimicrobial failure. CDC recommends retesting approximately three months after treatment and addressing relevant partners. Avoid sex for seven days after single-dose treatment or until a seven-day regimen is completed, symptoms resolve and partners are treated. Routine test of cure is generally unnecessary in appropriately treated nonpregnant patients.
Apply it
Arrange partner evaluation and treatment and schedule three-month retesting. In pregnancy, also arrange NAAT test of cure approximately four weeks after treatment completion to assess eradication.
Common pitfall: An early NAAT can detect nonviable organisms. Test of cure and later reinfection retesting have different purposes; pregnancy-specific confirmation of cure does not replace later retesting.
21.Why does migraine aura change combined contraceptive eligibility?
Migraine with aura is associated with increased ischemic stroke risk, and combined hormonal contraception adds vascular risk. CDC classifies combined pills, patches and rings as U.S. MEC category 4 with migraine aura, meaning unacceptable health risk. Migraine without aura is category 2 when other stroke risk factors are absent. Classification requires an accurate headache and aura history.
Apply it
Clarify recurrent focal visual or neurologic symptoms preceding headache. A confirmed aura history changes eligibility even in a young patient who does not smoke.
Common pitfall: Headache intensity alone does not identify aura. Switching from a combined pill to a combined patch or ring does not remove the restriction, and new or markedly changed headaches need evaluation.
22.How do smoking intensity and age affect combined contraception?
Smoking increases cardiovascular risk among combined contraceptive users, particularly myocardial infarction risk. U.S. MEC classifies smoking before age 35 as category 2 for combined hormonal contraception. At age 35 or older, fewer than 15 cigarettes daily is category 3, while 15 or more is category 4. Category 3 means risks usually outweigh advantages; category 4 means unacceptable risk.
Apply it
A 38-year-old smoking 20 cigarettes daily has category 4 eligibility. Discuss another suitable contraceptive method and offer smoking cessation support.
Common pitfall: Record cigarette quantity rather than tobacco use alone. A lower estrogen dose does not erase the classification, and other cardiovascular risks still require assessment.
23.When can STI screening accompany same-day IUD placement?
An asymptomatic patient with STI risk who is due for gonorrhea and chlamydia screening can generally be screened during IUD placement without delaying insertion. Risk factors alone do not establish infection. Current purulent cervicitis or known current gonorrhea or chlamydia precludes placement. Bimanual examination and cervical inspection help assess anatomy and findings that change eligibility.
Apply it
When pregnancy is reasonably excluded and examination shows no cervicitis, collect indicated screening specimens and proceed with placement if otherwise appropriate.
Common pitfall: A pending screening result differs from an already known infection. Permission for same-day screening does not authorize insertion through purulent cervicitis or a known active gonorrhea or chlamydia infection.
24.How do IUD type and cycle timing determine backup contraception?
Once pregnancy is reasonably excluded, IUD placement need not be restricted to menstruation. A copper IUD requires no additional contraception after insertion. For an LNG-IUD, no backup is needed when placement occurs within seven days after menstrual bleeding begins. Later placement generally requires seven days of abstinence or barrier protection. Special postpartum and method-switching circumstances have additional recommendations.
Apply it
After LNG-IUD placement ten days after bleeding began, provide seven-day backup instructions when the general cycle-timing rule applies. Give a specific date when backup can stop.
Common pitfall: Copper and LNG-IUD instructions are not interchangeable. A negative pregnancy test alone may not exclude a very early pregnancy after recent intercourse.
25.Which bleeding changes during IUD use need evaluation?
Copper IUDs commonly cause heavier or prolonged bleeding early in use. LNG-IUD users often experience initial spotting followed by lighter bleeding or amenorrhea. New heavy bleeding after an established pattern warrants consideration of displacement, pregnancy, STIs, thyroid disease or uterine pathology when indicated. Management incorporates symptoms, likely cause and the patient's preference to continue or remove the device.
Apply it
New heavy bleeding after two comfortable years with a copper IUD needs assessment rather than automatic attribution to early adjustment. Ask about pain and pregnancy risk.
Common pitfall: Expected early bleeding does not explain every later change. Uncomplicated LNG-IUD amenorrhea does not automatically require treatment, and a patient may request removal at any time.
26.Which emergency contraception choices remain useful after intercourse?
Emergency contraceptive pills should be taken as soon as possible within five days of unprotected intercourse. A copper IUD can be placed within five days of the first unprotected act and supplies continuing contraception. When ovulation can be estimated, insertion can sometimes occur later after intercourse if no more than five days have passed since ovulation. Ulipristal outperforms levonorgestrel pills during days three through five.
Apply it
Four days after condom failure, discuss an eligible patient's copper IUD and oral options, including effectiveness, preferences and continuing contraception needs.
Common pitfall: Do not declare all methods ineffective after 72 hours. Oral emergency contraception does not provide protection from subsequent intercourse or prevent sexually transmitted infections.
27.When should infertility evaluation begin?
ASRM's 2026 opinion recommends evaluation after 12 months of regular unprotected intercourse below age 35 and after six months at age 35 or older when no concerning etiology is known. More immediate evaluation may be warranted above 40. Irregular cycles, suspected tubal disease, endometriosis, male subfertility or another known concern justifies assessment without waiting.
Apply it
Begin evaluation for a 36-year-old after seven months of attempts. Evaluate a younger patient with amenorrhea promptly rather than requiring a full year of unsuccessful attempts.
Common pitfall: These intervals are not mandatory waiting periods for every patient. Relationship status and sexual orientation must not be used to deny or delay appropriate fertility care.
28.How should infertility evaluation address multiple contributors?
When a male partner contributes sperm, evaluation of both partners should begin together. Obtain reproductive and medical history and at least one semen analysis at the outset. The patient's assessment addresses ovulatory function and relevant uterine or tubal factors using appropriate, initially less invasive methods. History directs the need for physical examination rather than requiring every possible examination routinely.
Apply it
Arrange semen assessment concurrently with indicated ovulatory and anatomical evaluation. Include prior reproductive outcomes, medications, sexual dysfunction and relevant surgery in both histories.
Common pitfall: Previous paternity does not establish current semen quality. Completing every female test before considering a male factor delays identification of a potentially important contributor.
29.How do menstrual and endocrine findings direct fertility testing?
Regular, predictable cycles generally every 25–35 days support an ovulatory pattern in ASRM's 2026 opinion. Oligomenorrhea or amenorrhea establishes ovulatory dysfunction and warrants cause assessment after pregnancy is excluded. Elevated FSH with low estradiol favors ovarian insufficiency; low or normal FSH with low estradiol favors hypothalamic suppression. Endocrine tests should address clinical findings rather than form an indiscriminate panel.
Apply it
Galactorrhea with infrequent menses justifies prolactin testing. If ovulation confirmation is needed, progesterone approximately one week before expected menses is more useful than an automatic day-21 sample; above 3 ng/mL supports recent ovulation.
Common pitfall: A single progesterone value cannot establish luteal quality. Prolactin and thyroid testing are not universal requirements for an asymptomatic patient with a clearly ovulatory history.
30.How do menopausal symptoms and uterine status guide hormone treatment?
Declining ovarian estrogen can cause hot flashes, night sweats and vaginal dryness. Systemic estrogen is the most effective treatment for vasomotor symptoms. A patient with a uterus generally also needs progestogen because unopposed systemic estrogen stimulates endometrial proliferation and increases endometrial cancer risk; progestogen reduces that risk. Systemic hormone therapy is generally unsuitable with a history of breast or endometrial cancer, venous thromboembolism, stroke, myocardial infarction or liver disease. Unexplained vaginal bleeding requires evaluation before starting treatment. When systemic therapy is unsuitable, a nonhormonal medication such as gabapentin can reduce hot flashes. For isolated vaginal dryness, moisturizers, lubricants and appropriately selected low-dose local vaginal estrogen target vaginal symptoms; local estrogen does not provide systemic treatment of hot flashes.
Apply it
A patient with disruptive hot flashes, an intact uterus and no contraindications may consider systemic estrogen with endometrial protection after discussing benefits and risks. A prior pulmonary embolism changes treatment selection toward a nonhormonal option such as gabapentin. A patient reporting vaginal dryness without vasomotor symptoms needs treatment directed at vaginal tissue rather than systemic hormone exposure. Any unexplained bleeding changes the immediate priority to diagnostic evaluation.
Common pitfall: Adding progestogen protects the endometrium but does not eliminate systemic estrogen's thromboembolic or cardiovascular risks. Choosing a transdermal route does not automatically make systemic therapy appropriate after thrombosis. Low-dose local vaginal treatment is a separate symptom-specific decision, not a substitute for nonhormonal treatment of hot flashes or automatic permission to use estrogen in every cancer survivor.
2026 Candidate Guide: Women's Health Care Nurse Practitioner · Hormone Therapy for Menopause | ACOG
31.How should abnormal uterine bleeding be evaluated and initially managed?
First assess bleeding severity, vital signs and pregnancy possibility. Clarify timing, duration, medications and a personal or family bleeding history; obtain a CBC and directed testing. Structural disease, ovulatory dysfunction and coagulopathy require different evaluation. ACOG recommends first-line endometrial sampling in patients older than 45 with AUB and sampling in younger patients with persistent bleeding, unopposed estrogen exposure or failed treatment. Eligible stable patients often receive medical treatment, including hormonal methods. See [ACOG acute AUB guidance](https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2013/04/management-of-acute-abnormal-uterine-bleeding-in-nonpregnant-reproductive-aged-women).
Apply it
Persistent irregular bleeding in a 48-year-old warrants endometrial assessment. Heavy bleeding with faintness or instability requires emergency stabilization before a routine outpatient workup.
Common pitfall: Perimenopause does not explain away persistent bleeding. Symptom suppression alone does not exclude endometrial disease, and normal imaging cannot answer every histologic question.
2026 Candidate Guide: Women's Health Care Nurse Practitioner
32.How does postmenopausal bleeding change malignancy assessment?
Bleeding presumed to arise from the uterus at least 12 months after the final menstrual period requires evaluation for endometrial malignancy and benign causes. ACOG's 2026 update recommends transvaginal ultrasonography plus endometrial tissue sampling for most patients. Initial biopsy may be omitted only when every exception criterion is satisfied: a single bleeding episode, a fully visualized endometrium measuring 4 mm or less, no factors strongly associated with malignancy, and access to prompt gynecologic evaluation and follow-up. Counseling must explicitly state that continued or recurrent bleeding requires immediate reevaluation. Strongly associated risk examples include BMI above 30, diabetes mellitus, tamoxifen or other selective estrogen receptor modulator exposure, exogenous estrogen exposure, nulliparity, known or suspected Lynch or Cowden syndrome, and family history of endometrial cancer.
Apply it
A patient with one bleeding episode, a fully visualized 3-mm endometrium, no strongly associated risk factors and reliable access to prompt care may discuss initially deferring biopsy, provided immediate reevaluation for continued or recurrent bleeding is clearly explained. A patient with the same measurement but diabetes, BMI of 34 or tamoxifen exposure does not satisfy the exception. Ultrasound assesses anatomy and thickness; tissue sampling assesses histology.
Common pitfall: A thin endometrium alone cannot exclude malignancy; some aggressive cancers produce little thickening. An incompletely visualized endometrium also fails the exception. ACOG additionally identifies an association between Black race and high-grade cancers, while explaining that race is a social construct and disparities involve structural, care-related and other factors. Apparent atrophy or normal cervical screening does not independently exclude endometrial cancer.
2026 Candidate Guide: Women's Health Care Nurse Practitioner · ACOG Publishes Updated Guidance on Evaluation of Postmenopausal Bleeding | ACOG - College · ACOG Clinical Practice Update: Updated Guidance... : Obstetrics & Gynecology
33.Which cues distinguish common causes of vaginitis?
BV favors thin discharge, clue cells and elevated pH. Candida favors vulvar pruritus, erythema, thick discharge and yeast forms on KOH microscopy, usually with pH below 4.5. Trichomoniasis can show motile organisms, but wet-mount sensitivity is limited; use a suitable NAAT when suspicion persists after a negative wet mount. Elevated pH alone cannot distinguish BV from trichomoniasis. See [CDC vaginitis assessment](https://www.cdc.gov/std/treatment-guidelines/vaginal-discharge.htm) and [Candida guidance](https://www.cdc.gov/std/treatment-guidelines/candidiasis.htm).
Apply it
Pruritus with normal pH and yeast supports candidiasis. Odor with elevated pH but no organisms on microscopy requires further interpretation or testing rather than automatic antifungal treatment.
Common pitfall: A negative wet mount does not exclude yeast or trichomoniasis. Asymptomatic Candida colonization is not itself an indication for treatment, and persistent pathogen-negative inflammation suggests noninfectious causes.
34.How do pain patterns distinguish endometriosis from acute pelvic emergencies?
Cyclical pelvic pain, activity-limiting dysmenorrhea, deep dyspareunia and cyclical bowel or urinary symptoms support suspected endometriosis. NICE recommends ultrasound even with a normal examination and permits initial hormonal treatment alongside investigation; normal imaging does not exclude disease. Persistent symptoms, treatment failure or suspected deep disease warrant referral. Sudden severe unilateral pain with nausea raises concern for ovarian torsion or cyst complications. See [NICE endometriosis guidance](https://www.nice.org.uk/guidance/ng73/chapter/Recommendations) and [NHS ovarian cyst guidance](https://www.nhs.uk/conditions/ovarian-cyst/).
Apply it
For chronic cyclical pain, discuss appropriate analgesic or hormonal management and targeted assessment. New abrupt severe pain requires urgent assessment, including pregnancy evaluation when relevant.
Common pitfall: Do not attribute an acute change to known endometriosis without reassessment. A normal examination or ultrasound does not rule out endometriosis, and hormonal suppression must fit reproductive goals.
2026 Candidate Guide: Women's Health Care Nurse Practitioner
35.How should fertility assessment be tailored for LGBTQ+ patients?
Assessment follows reproductive goals, anatomy and the planned contribution of sperm, oocytes or gestation. Patients using donor sperm can warrant targeted evaluation without first attempting heterosexual intercourse. In reciprocal IVF, the oocyte contributor and gestational carrier have different assessment needs. Transgender men and nonbinary patients require an evaluation matched to their intended fertility treatment.
Apply it
Clarify each person's planned reproductive role, then select relevant history, laboratory studies and anatomical assessment. Explain the purpose of potentially distressing examinations and support shared decisions.
Common pitfall: Identity does not specify organs, exposure or treatment role. An irrelevant intercourse waiting period must not obstruct appropriate evaluation, and identical testing may be inappropriate for partners with different roles.
Obstetrics29%
36.Why is urine culture screening important during pregnancy?
Asymptomatic bacteriuria matters during pregnancy because treatment reduces pyelonephritis risk. USPSTF recommends a midstream clean-catch urine culture at the first prenatal visit or at 12–16 weeks, whichever is earlier. Culture identifies bacterial growth and supports organism-directed treatment. Absence of dysuria does not remove the screening indication because the targeted condition is asymptomatic.
Apply it
At an initial prenatal visit at ten weeks, obtain the culture rather than waiting for the later gestational interval or for urinary symptoms to develop.
Common pitfall: A negative dipstick or symptom review does not replace the recommended culture. The recommendation against routine screening of healthy nonpregnant adults cannot be transferred to prenatal care.
37.When should Tdap be given during pregnancy?
CDC recommends Tdap during each pregnancy, optimally at 27–36 weeks and preferably early in that interval. Maternal vaccination generates antibodies that cross the placenta and protect the infant before the infant's own series provides protection. A previous pregnancy dose does not replace vaccination during the current pregnancy. Tdap can be given at another gestational time when specifically indicated.
Apply it
Recommend Tdap at 28 weeks even if the patient received it during a pregnancy two years earlier. Explain that the goal is antibody protection for this infant.
Common pitfall: The ordinary booster interval does not replace pregnancy-specific guidance. Postpartum vaccination cannot provide prenatal placental antibody transfer, and the optimal interval is not an absolute safety boundary.
38.How does vaccine formulation determine pregnancy eligibility?
CDC recommends an appropriate inactivated or recombinant influenza vaccine during any trimester. Live attenuated intranasal influenza vaccine is contraindicated during pregnancy. MMR and varicella vaccines are also contraindicated; plan indicated vaccination before conception or postpartum. Avoid pregnancy for 28 days after MMR and one month after each varicella dose. Inadvertent administration warrants counseling rather than automatic pregnancy termination.
Apply it
Offer an appropriate influenza vaccine during the first trimester in influenza season. For rubella nonimmunity, explain the postpartum MMR plan rather than administering live vaccine during pregnancy.
Common pitfall: A restriction on one live formulation does not make all vaccines inappropriate. Lack of immunity does not override a pregnancy contraindication to a live vaccine.
39.How should cell-free DNA screening results guide prenatal decisions?
SMFM recommends routinely offering cfDNA screening for trisomies 21, 18 and 13 to all obstetric patients after counseling. Patients may decline screening or choose diagnostic testing. A positive result requires counseling, anatomical assessment and an offer of CVS or amniocentesis; it is not diagnostic. Placental trophoblast DNA supplies the pregnancy-associated signal, so placental mosaicism can produce discordance. A negative result lowers risk for assessed conditions but does not exclude all abnormalities or replace the anatomical survey.
Apply it
After a positive screen, discuss diagnostic confirmation before an irreversible decision. Explain that routine microdeletion screening is not recommended and sex chromosome screening is an opt-in choice.
Common pitfall: High sensitivity does not make every positive result a fetal diagnosis. Repeating screening does not provide the same evidence as diagnostic testing.
FDA Warns of Risks Associated with Non-Invasive Prenatal Screening Tests · Society for Maternal‐Fetal Medicine Consult Series #74: Cell‐free DNA screening for aneuploidies: Updated guidance - PMC
40.Which pregnancy platelet changes can reflect normal adaptation?
Platelet counts commonly decline during pregnancy. Hemodilution and increased platelet turnover, including placental sequestration and consumption, contribute to gestational thrombocytopenia. A mild, isolated late-pregnancy decrease without bleeding or smear abnormalities favors this pattern and generally needs no specific treatment. Counts below 100 × 10^9/L, early onset, pre-existing thrombocytopenia or bleeding history require further investigation. The physiological explanation must fit the complete presentation.
Apply it
An asymptomatic late-pregnancy patient with stable platelets of 135 × 10^9/L and no other abnormalities may have gestational thrombocytopenia. Hemolysis, liver injury or systemic symptoms instead demand assessment for another cause.
Common pitfall: Normal adaptation does not explain every low count. Exclude HELLP when clinically indicated, and consider specimen-related platelet clumping when a result is unexpectedly low.
41.How should fetal movement concerns be triaged?
Movement is usually first perceived between 16 and 24 weeks, sometimes after 20 weeks in a first pregnancy. Contact the maternity clinician if none has been felt by 24 weeks. Once a usual pattern is established, a meaningful reduction or change warrants immediate maternity contact. NHS guidance emphasizes the individual pattern rather than one universal daily count.
Apply it
At 33 weeks, substantially fewer movements require immediate contact and assessment even if a home Doppler detects a heartbeat. Explain the action before the patient leaves routine prenatal care.
Common pitfall: Do not wait overnight or use a home heartbeat signal as proof of wellbeing. The normal interval for initial perception cannot explain loss of an established movement pattern.
42.How quickly must severe obstetric hypertension be confirmed and treated?
Severe pressure is systolic at least 160 mm Hg or diastolic at least 110 mm Hg. Reassess rapidly over approximately 15 minutes while activating emergency obstetric coordination. Persistent severe hypertension requires antihypertensive treatment as soon as possible within 30–60 minutes; SMFM measures timeliness from the first severe reading. Appropriate acute options include intravenous labetalol, intravenous hydralazine or immediate-release oral nifedipine. Magnesium sulfate prevents or treats seizures when indicated; it does not replace blood-pressure treatment.
Apply it
A reading of 164/96 meets severe range through the systolic component. Repeat promptly, assess symptoms and initiate the emergency pathway without waiting for a four-hour confirmation interval or urine protein results.
Common pitfall: Either component suffices, and the rule applies antepartum, intrapartum and postpartum. Extended-release nifedipine is not the rapid-acting formulation used for acute treatment.
43.Why does absent proteinuria not exclude preeclampsia?
Preeclampsia requires new hypertension after 20 weeks in a previously normotensive patient: systolic pressure at least 140 mm Hg or diastolic pressure at least 90 mm Hg, ordinarily documented twice at least four hours apart. Proteinuria qualifies at 300 mg or more per 24 hours or a urine protein/creatinine ratio of at least 0.3 mg/mg. Without proteinuria, hypertension plus qualifying organ dysfunction establishes the diagnosis: platelets below 100 × 10^9/L; creatinine above 1.1 mg/dL or doubled without another renal explanation; liver transaminases at least twice the upper limit of normal; pulmonary edema; new headache unresponsive to medication and unexplained by another diagnosis; or visual symptoms. These thresholds distinguish diagnostic findings from nonspecific complaints. See the [ACOG diagnostic criteria](https://www.acog.org/community/districts-and-sections/district-iv/whats-new/countdown-to-intern-year-week-3-hypertensive-disorders).
Apply it
At 32 weeks, blood pressures of 146/94 and 148/96 mm Hg four hours apart, platelets of 88 × 10^9/L and a protein/creatinine ratio of 0.12 support preeclampsia with severe features because the platelet count meets the organ-dysfunction threshold. Severe hypertension follows a faster pathway: systolic pressure at least 160 or diastolic pressure at least 110 mm Hg requires prompt reassessment within minutes. Persistent severe hypertension requires emergency treatment as soon as possible, within 30–60 minutes of onset; do not wait four hours or for protein testing.
Common pitfall: Edema alone does not diagnose preeclampsia, and an ordinary headache that resolves with medication does not meet the qualifying neurologic criterion. These findings still warrant assessment when clinically concerning. Conversely, absent proteinuria cannot negate qualifying thrombocytopenia, renal or hepatic injury, pulmonary edema, or neurologic findings accompanying new hypertension.
Preeclampsia, High Blood Pressure and Maternal Health | American Heart Association · NICHD — Preeclampsia and Eclampsia · Quality_metrics_htn.pdf
44.Which findings identify HELLP or eclampsia?
HELLP denotes hemolysis, elevated liver enzymes and low platelets. Upper abdominal pain, nausea or bruising can accompany this serious multisystem pattern, which may occur without hypertension or proteinuria. Eclampsia involves seizures associated with preeclampsia and can occur before, during or after birth. Both require emergency assessment, with immediate stabilization for a new seizure while other causes are considered.
Apply it
Hemolysis, liver injury and thrombocytopenia with right upper quadrant pain warrant urgent obstetric care even when the blood pressure is normal.
Common pitfall: Do not require every classic preeclampsia feature before recognizing HELLP. Delivery does not eliminate the possibility of a hypertensive emergency or an eclamptic seizure.
NICHD — Preeclampsia and Eclampsia · Recommendations of the AGG (Obstetrics and Prenatal Medicine Working Group, Section Maternal Diseases) on Maternal Thrombocytopenia in Pregnancy - PMC
45.How should gestational dating guide interpretation of later growth?
First-trimester ultrasound through 13 weeks 6 days is the most accurate way to establish or confirm gestational age, using crown–rump length when appropriate. LMP dating assumes a 28-day cycle and can be unreliable with uncertain dates or irregular ovulation. Establish and document the best estimated due date early; later changes should be rare. ART pregnancies use embryo age and transfer timing. See [ACOG dating guidance](https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/05/methods-for-estimating-the-due-date).
Apply it
When an early reliable date is established but later measurements are small, assess growth rather than routinely moving the due date. Before nine weeks, an ultrasound–LMP discrepancy greater than five days supports redating under ACOG guidance.
Common pitfall: Third-trimester dating is less reliable and can conceal growth restriction. LMP alone should not determine whether a heartbeat must be visible on an early scan.
46.Who qualifies for expectant treatment of a confirmed tubal ectopic pregnancy?
NICE offers expectant management to clinically stable, pain-free patients with a confirmed tubal ectopic mass under 35 mm, no visible heartbeat, hCG at most 1,000 IU/L and reliable follow-up. It considers observation when hCG is above 1,000 but below 1,500 IU/L if the other criteria are met. Repeat hCG on days 2, 4 and 7; falls of at least 15% from each preceding value permit weekly testing until below 20 IU/L. Inadequate decline requires clinical review and senior advice.
Apply it
Explain emergency access and the complete monitoring schedule before observation. If methotrexate is selected instead, NICE uses days 4 and 7 followed by weekly hCG, with reassessment for plateauing or rising results.
Common pitfall: These criteria concern a confirmed tubal ectopic, not an unlocated pregnancy. Rupture remains possible during observation or after methotrexate; worsening pain or fainting overrides the scheduled pathway.
47.Which symptoms suggest a ruptured ectopic pregnancy?
An ectopic pregnancy implants outside the uterine cavity, most often in a fallopian tube. Rupture can cause life-threatening internal bleeding. Sudden severe abdominal pain with dizziness, fainting or pallor requires emergency evaluation when pregnancy is possible. Visible vaginal blood loss may be slight despite major internal hemorrhage. Clinical instability takes priority over a scheduled outpatient investigation.
Apply it
A positive pregnancy test with severe pain and near-syncope requires emergency transport and assessment. Do not wait for the next hormone measurement or a routine ultrasound appointment.
Common pitfall: Minimal spotting does not establish stability. A previous diagnosis, reassuring trend or treatment plan cannot exclude rupture when new emergency symptoms develop.
NHS — Ectopic Pregnancy · Ectopic pregnancy - Treatment - NHS
48.How does diagnostic follow-up of pregnancy of unknown location differ from ectopic observation?
Pregnancy of unknown location can represent an early intrauterine pregnancy, a failing pregnancy or an ectopic pregnancy. NICE uses two hCG measurements approximately 48 hours apart, never earlier, with symptoms taking priority. A rise greater than 63% suggests a developing intrauterine pregnancy but does not exclude ectopic pregnancy; arrange ultrasound in 7–14 days, earlier when hCG is at least 1,500 IU/L. A fall greater than 50% leads to a urine test 14 days after the second measurement. Lesser changes require clinical review within 24 hours.
Apply it
A positive urine test after the specified falling-hCG follow-up requires review within 24 hours. Continue diagnostic assessment until location or resolution is established and provide continuous access instructions for worsening symptoms.
Common pitfall: hCG need not decline in an unlocated pregnancy. An apparently appropriate rise does not prove location, and the confirmed-ectopic observation schedule must not be substituted for this diagnostic pathway.
49.How does perinatal depression differ from baby blues?
Baby blues involves mild, short-lived emotional changes during the first two weeks after birth. Severe symptoms, persistence beyond two weeks or impaired functioning require assessment for depression and safety concerns. Perinatal depression can begin during pregnancy. Psychotherapy, medication or both can help. Treatment selection incorporates severity, previous response and pregnancy or breastfeeding circumstances.
Apply it
At five weeks postpartum, persistent hopelessness and inability to sleep despite opportunity warrant depression and safety assessment with a treatment plan. Discuss psychotherapy and medication options according to the evaluation.
Common pitfall: Do not wait two weeks through severe symptoms or danger. Antidepressants often take several weeks for full benefit, and abrupt discontinuation solely because pregnancy is recognized can create problems.
50.Which postpartum mental symptoms require emergency assessment?
Hallucinations and delusions are psychotic symptoms. Suspected postpartum psychosis requires immediate emergency care and usually hospitalization to protect the patient and infant. New mania or marked confusion also requires urgent assessment for psychiatric and medical causes. Neither finding alone proves psychosis, but routine follow-up is inadequate when the presentation suggests an acute severe disorder.
Apply it
A patient who hears commands involving the infant or holds a fixed false belief about the infant needs emergency assessment and immediate safety arrangements, even without stated suicidal intent.
Common pitfall: Family supervision and sleep advice do not replace emergency care for suspected psychosis. Do not equate every confused or manic presentation with an established diagnosis before assessment.
51.How should NST and biophysical profile findings change management?
A reactive nonstress test (NST) generally requires at least two qualifying fetal heart-rate accelerations within 20 minutes. At 32 weeks or later, each must rise at least 15 beats/min above baseline and last at least 15 seconds. Before 32 weeks, the commonly used threshold is at least 10 beats/min for at least 10 seconds. If accelerations are insufficient, observation commonly extends to 40 minutes to allow for fetal sleep before classifying the NST as nonreactive. Nonreactivity requires further evaluation but does not independently prove hypoxia; sleep, prematurity and medication effects can reduce reactivity. The full biophysical profile (BPP) assigns 0 or 2 points each for NST reactivity, fetal breathing, movement, tone and amniotic fluid. Scores of 8–10 with adequate fluid are reassuring; 6 is equivocal and may prompt repeat testing within 24 hours or delivery depending on gestational age and other findings. Scores of 4 or less require prompt assessment and consideration of delivery. See [ACOG fetal testing guidance](https://www.acog.org/womens-health/faqs/special-tests-for-monitoring-fetal-well-being) and [antenatal surveillance guidance](https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2021/06/indications-for-outpatient-antenatal-fetal-surveillance).
Apply it
At 30 weeks, two accelerations rising 12 beats/min and lasting 12 seconds within 20 minutes meet the commonly used preterm reactivity threshold. At 34 weeks, those same accelerations do not meet the 15-beat/min, 15-second threshold, so continue observation when the remaining tracing is reassuring. Persistent nonreactivity can lead to a BPP. An equivocal BPP near term may favor delivery, whereas an otherwise stable pregnancy remote from term may warrant repeat testing within 24 hours.
Common pitfall: Do not apply the term acceleration threshold automatically to a fetus before 32 weeks. Do not diagnose hypoxia from insufficient accelerations alone. Interpret the total BPP alongside amniotic fluid, gestational age and the clinical presentation; low fluid needs attention even with an otherwise reassuring score. Concerning decelerations require prompt assessment rather than simply waiting for the observation period to end.
2026 Candidate Guide: Women's Health Care Nurse Practitioner
52.Which postpartum findings distinguish hemorrhage from uterine infection?
Heavy bleeding with a soft, poorly contracted uterus suggests atony; failure of uterine contraction leaves placental-site vessels inadequately compressed. Activate hemorrhage care, assess blood loss and circulation, and begin uterine massage and uterotonic treatment while assessing other bleeding sources. WHO's first-response bundle includes oxytocin, tranexamic acid, intravenous fluids, examination and escalation; early TXA is given within three hours of birth for PPH. Fever, uterine or abdominal tenderness and foul discharge suggest endometritis, usually requiring intravenous antibiotics. See [WHO hemorrhage recommendations](https://www.ncbi.nlm.nih.gov/books/NBK619236/?report=reader) and [ACOG postpartum complications](https://www.acog.org/womens-health/experts-and-stories/the-latest/3-conditions-to-watch-for-after-childbirth).
Apply it
A boggy uterus with brisk bleeding requires an immediate coordinated hemorrhage response. Several days later, fever and foul discharge require assessment and treatment for infection, which can also contribute to abnormal bleeding.
Common pitfall: Expected lochia does not explain gushing blood, faintness or systemic illness. Continued bleeding with good uterine tone requires assessment for other causes such as trauma or retained tissue.
2026 Candidate Guide: Women's Health Care Nurse Practitioner
Pharmacology10%
53.How do gestational age and duration change NSAID precautions?
From about 20 weeks, NSAIDs can impair fetal renal function, reducing fetal urine production and causing oligohydramnios. If necessary between 20 and 30 weeks, use the lowest effective dose for the shortest duration. Consider amniotic-fluid ultrasound monitoring when treatment exceeds 48 hours and discontinue if oligohydramnios occurs. Avoid NSAIDs at 30 weeks and later because of premature ductus arteriosus closure.
Apply it
Repeated ibuprofen use at 24 weeks requires review of necessity, exposure duration and possible fluid monitoring rather than routine over-the-counter approval.
Common pitfall: The renal warning begins before the third trimester. FDA explicitly excepts prescribed 81-mg aspirin for specified pregnancy indications, so do not automatically discontinue that treatment under the analgesic warning.
54.Why is ibuprofen often preferred during breastfeeding?
LactMed identifies ibuprofen as a preferred analgesic or anti-inflammatory option during breastfeeding because milk levels are extremely low, its half-life is short and infant exposure is far below therapeutic infant doses. This judgment depends on exposure through milk rather than the drug name alone. Maternal contraindications and the infant's clinical circumstances still matter when selecting treatment.
Apply it
For a breastfeeding parent with a healthy term infant and no maternal contraindication, short-term ibuprofen generally does not require interrupting feeds. Explain the low-exposure rationale.
Common pitfall: Low milk transfer does not erase maternal renal, gastrointestinal or allergy concerns. Pregnancy restrictions cannot simply be carried into lactation because exposure pathways and risks differ.
55.How is relative infant dose calculated?
Relative infant dose compares the infant's estimated milk-borne dose in mg/kg/day with the maternal dose in mg/kg/day, multiplied by 100. Weight adjustment is essential because the parent and infant have very different body sizes. The calculation describes relative exposure rather than providing a complete safety verdict. Drug toxicity, infant maturity and clinical circumstances still affect interpretation.
Apply it
A 60-kg parent taking 1,200 mg/day receives 20 mg/kg/day. If infant exposure is 0.06 mg/kg/day, the relative infant dose is 0.06 divided by 20 times 100, or 0.3%.
Common pitfall: Dividing weight-adjusted infant exposure by the unadjusted maternal daily total mixes unlike measures. A small percentage does not establish universal safety for every medicine or infant.
56.How can enzyme-inducing medicines affect contraception?
Some medicines increase metabolism of contraceptive hormones and reduce combined hormonal contraceptive effectiveness. CDC identifies interactions with agents such as carbamazepine, phenytoin and rifampin; these combinations generally fall in U.S. MEC category 3. Medication reconciliation must consider loss of effectiveness as well as toxicity. The interaction depends on the actual medicine rather than its broad therapeutic class.
Apply it
For a patient taking carbamazepine, discuss a suitable contraceptive approach and coordinate medication decisions. Do not abruptly discontinue antiseizure treatment simply to preserve the existing contraceptive prescription.
Common pitfall: Most broad-spectrum antibiotics do not share rifampin's interaction. Combined contraception can instead lower lamotrigine concentrations, so the direction and clinical consequence of an interaction must be identified.
57.Why is hormonal contraception delayed after ulipristal?
Ulipristal has antiprogestin activity, so starting a progestin-containing method too soon can reduce its ovulation-delaying effect. CDC generally advises starting or resuming hormonal contraception no sooner than five days after ulipristal. Use barriers or abstinence during the delay and for seven days after starting, or until the next menses, whichever occurs first. Nonhormonal methods can begin immediately.
Apply it
Give a specific restart date and protection instructions covering both the waiting interval and the period after hormonal contraception begins. Provider-dependent methods require weighing delayed access against interaction risk.
Common pitfall: After levonorgestrel emergency contraception, hormonal contraception can begin immediately. Do not apply the ulipristal delay to every emergency pill or omit protection while waiting.
58.How can oral iron effectiveness and tolerability be improved?
Oral iron replenishes available body iron, but absorption and tolerability influence success. Vitamin C-containing foods support absorption, while black tea can reduce it. Constipation, nausea and upset stomach can undermine adherence. Administration or preparation adjustments may improve tolerance, and some patients require intravenous replacement. Restoring iron levels often takes months rather than ending when fatigue first improves.
Apply it
For constipation and administration with black tea, address both tolerability and absorption. Review adherence, arrange response assessment and continue investigating the reason for deficiency.
Common pitfall: Repeating an intolerable prescription without adjustment is unlikely to improve adherence. Symptom improvement does not independently prove complete restoration of stores or resolution of ongoing blood loss.
Professional Practice Issues3%
59.What makes consent valid, and when can emergency treatment proceed?
Informed consent requires understanding, voluntariness and authorization for a specific intervention. Explain the diagnosis when known, purpose, risks, benefits, alternatives and forgoing treatment, then document the discussion and decision. The general ethical emergency exception involves urgently necessary treatment when the patient cannot participate and a surrogate is unavailable. Revisit consent when participation becomes possible. Certification recognizes knowledge; jurisdictional regulation separately determines practice authority.
Apply it
Pause an elective procedure when a patient believes refusal would end access to care. Clarify options and voluntariness before obtaining a decision, while practising within applicable legal authority.
Common pitfall: A signature alone is insufficient. A capable patient's informed refusal cannot be bypassed because treatment is recommended, and consent cannot create legal practice authority.
2.1.1.pdf · 2026 Candidate Guide: Women's Health Care Nurse Practitioner
60.How can a safety metric guide improvement without overstating the evidence?
A process measure assesses whether recommended care occurred; an outcome measure assesses what happened to patients. SMFM's severe-hypertension metric tracks timely response within 60 minutes of the first persistent severe episode, using standardized pressure and medication timestamps. Review delayed cases for missed repeat measurements, communication failures or medication access barriers. Track balancing measures such as maternal hypotension. Improved timeliness supports better implementation but does not by itself prove a reduction in stroke or establish causation.
Apply it
After introducing an emergency algorithm, compare timely-response rates using the same definitions and review hypotension rates. Confirm suspicious timestamps and examine concurrent changes before attributing improvement entirely to the algorithm.
Common pitfall: A process target cannot guarantee a clinical outcome. Changing the denominator or starting the clock at a delayed confirmatory reading can make performance appear better while concealing unsafe delays.
Quality_metrics_htn.pdf · 2026 Candidate Guide: Women's Health Care Nurse Practitioner
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Prioritize gynecologic and reproductive health and obstetrics, which together account for 62% of the published outline.
- Use complaint-directed histories and examinations to localize disease and identify findings that change urgency.
- Distinguish screening, diagnostic confirmation and follow-up testing by purpose, population and specimen.
- Compare general-health presentations, including hypertension, thyroid disease, asthma, urinary symptoms and anemia.
- Apply contraception eligibility, emergency contraception timing and method-specific backup instructions.
- Distinguish menopause symptoms, abnormal bleeding, malignancy concerns, vaginitis and pelvic pain patterns.
- Use targeted infertility evaluation, concurrent partner assessment and reproductive goals to select appropriate tests.
- Interpret gestational dating, maternal adaptation and fetal surveillance alongside pregnancy and postpartum complications.
- Connect pharmacokinetics, interactions and gestational timing to medication decisions.
- Apply consent principles and distinguish safety processes, clinical outcomes and evidence limitations.
- Use the official outline to identify additional disorders, procedures and competencies beyond these selected concepts.
A practical preparation plan
1. Map the official outline
Use pages 7–9 of NCC's 2026 guide as the full preparation framework. Review the detailed topics on pages 10–15 and mark areas requiring study beyond this selection.
2. Identify the decisive finding
For each concept, explain which history detail, examination finding or test result changes the differential or action. Compare stable outpatient presentations with findings requiring emergency coordination.
3. Practise criteria and timing
Reconstruct PID treatment, contraceptive eligibility, IUD backup rules, severe-hypertension response times and the distinct pathways for confirmed ectopic pregnancy and pregnancy of unknown location.
4. Complete the practice cases
Answer the 20 questions independently. Explain why every alternative fits or fails before reading the explanation, then identify the clinical distinction underlying each error.
5. Use delayed active recall
Review flashcard fronts without reading their backs. Revisit missed cases after a delay and justify the answer from clinical findings rather than option position.
6. Extend preparation
Study remaining official-outline topics and current primary clinical guidance. Review NCC's current candidate and testing guides before the examination.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- NCC — Women's Health Care Nurse Practitioner
- 2026 Candidate Guide: Women's Health Care Nurse Practitioner
- NHLBI — Iron-Deficiency Anemia
- FDA Warns of Risks Associated with Non-Invasive Prenatal Screening Tests
- USPSTF — Breast Cancer: Screening
- USPSTF — Osteoporosis to Prevent Fractures: Screening
- USPSTF — Prediabetes and Type 2 Diabetes: Screening
- CDC — Bacterial Vaginosis
- CDC — Pelvic Inflammatory Disease
- CDC — Chlamydial Infections
- CDC — Classifications for Combined Hormonal Contraceptives
- CDC — Intrauterine Contraception
- CDC — Emergency Contraception
- ASRM — Fertility Evaluation of Infertile Women: A Committee Opinion
- NICHD — Preeclampsia and Eclampsia
- NHS — Ectopic Pregnancy
- USPSTF — Asymptomatic Bacteriuria in Adults: Screening
- CDC — Guidelines for Vaccinating Pregnant Women
- NHS — Your Baby's Movements
- NIMH — Perinatal Depression
- LactMed — Ibuprofen, revised August 15, 2025
- FDA — NSAID Use at 20 Weeks or Later in Pregnancy
- AMA Code of Medical Ethics — Informed Consent
- Society for Maternal‐Fetal Medicine Consult Series #74: Cell‐free DNA screening for aneuploidies: Updated guidance - PMC
- Final Recommendation Statement: Prediabetes and Type 2 Diabetes: Screening | United States Preventive Services Taskforce
- Fertility evaluation of infertile women: a committee opinion (2026) | American Society for Reproductive Medicine | ASRM
- Fertility evaluation of infertile women: a committee opinion - PubMed
- Preeclampsia, High Blood Pressure and Maternal Health | American Heart Association
- Ectopic pregnancy - Treatment - NHS
- 2.1.1.pdf
- Society for Maternal-Fetal Medicine Special Statement: A quality metric for evaluating timely treatment of severe hypertension - SMFM Publications and Clinical Guidelines
- Quality_metrics_htn.pdf
- Management of tubal ectopic pregnancy | Ectopic pregnancy and miscarriage: diagnosis and initial management | Guidance | NICE
- Diagnosis of viable intrauterine pregnancy and of tubal ectopic pregnancy | Ectopic pregnancy and miscarriage: diagnosis and initial management | Guidance | NICE
- Recommendations of the AGG (Obstetrics and Prenatal Medicine Working Group, Section Maternal Diseases) on Maternal Thrombocytopenia in Pregnancy - PMC
- Asthma - Asthma Attack | NHLBI, NIH
- Thyroid Tests - NIDDK
- Hypothyroidism (Underactive Thyroid) - NIDDK
- Symptoms & Causes of Bladder Infection in Adults - NIDDK
- Treatment for Bladder Infection in Adults - NIDDK
- Ovarian cyst - NHS
- Hormone Therapy for Menopause | ACOG
- Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women | ACOG - College
- ACOG Publishes Updated Guidance on Evaluation of Postmenopausal Bleeding | ACOG - College
- ACOG Clinical Practice Update: Updated Guidance... : Obstetrics & Gynecology
- Recommendations | Endometriosis: diagnosis and management | Guidance | NICE
- Methods for Estimating the Due Date | ACOG - College
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.